Exodus Point Capital Management, LP Arbutus Biopharma Corp Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$3.11 - $4.61 $68,992 - $102,268	-22,184 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $58,787 - $102,490	22,184 New	22,184 $95,000
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $400,120 - $561,768	-160,048 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $133,669 - $206,038	42,570 Added 36.24%	160,048 $533,000
Q4 2020 Feb 16, 2021	BUY	$2.76 - $4.97 $288,513 - $519,533	104,534 Added 807.59%	117,478 $417,000
Q3 2020 Nov 16, 2020	SELL	$1.75 - $6.2 $7,098 - $25,147	-4,056 Reduced 23.86%	12,944 $41,000
Q2 2020 Aug 14, 2020	BUY	$0.91 - $2.36 $2,849 - $7,389	3,131 Added 22.58%	17,000 $31,000
Q1 2020 May 15, 2020	SELL	$1.01 - $3.42 $22,916 - $77,599	-22,690 Reduced 62.06%	13,869 $14,000
Q4 2019 Feb 14, 2020	SELL	$0.87 - $2.89 $2,732 - $9,077	-3,141 Reduced 7.91%	36,559 $102,000
Q3 2019 Nov 14, 2019	BUY	$1.34 - $2.4 $53,198 - $95,280	39,700 New	39,700 $61,000

138

95.5M

3.44M

377K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $577M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.